ABC | Volume 111, Nº6, Dezembro 2018

Artigo Original Radaelli et al Estatinas para tratar crianças: uma meta-análise Arq Bras Cardiol. 2018; 111(6):810-821 Apêndice III Apêndice IV Apêndice 3 – Gráfico mostrando o efeito da terapia com estatinas nos níveis de colesterol lipoproteína de baixa densidade (LDL). 44 42 24 26 26 18 17 18 90 35 35 63 63 63 140 106 106 106 106 126 126 1424 44 117,00 128,00 131,09 144,40 125,77 133,33 156,80 140,07 173,85 190,76 176,30 179,75 183,23 183,89 180,90 182,00 155,50 208,33 168,50 103,47 114,10 143,00 33,00 40,00 40,90 48,44 31,00 46,89 38,60 46,14 20,88 6,06 34,50 29,39 6,12 6,12 3,65 3,50 25,13 59,70 40,00 47,20 53,30 2,71 15 15 16 47 27 27 27 69 69 69 59 19 19 120 120 1053 61 88 108 6 6 6 60 227,00 227,00 228,93 239,20 214,85 227,00 215,91 239,20 208,47 239,57 255,00 239,20 239,57 242,50 239,57 236,50 237,00 206,30 252,00 209,00 134,60 144,08 16,58 16,58 8,12 61,10 54,51 15,83 55,69 61,10 61,10 54,36 56,20 55,50 3,69 3,59 36,00 44,80 4,40 4,40 4,16 7,14 7,14 7,07 4,7% 4,6% 5,1% 3,6% 4,5% 4,8% 4,5% 4,5% 4,6% 4,8% 3,8% 3,4% 4,9% 4,4% 4,9% 5,1% 5,1% 5,1% 5,1% 5,1% 100% 3,7% 3,6% [–122,86; –97,14] [–113,49; –84,51] [–100,20; –95,48] [–123,06; –66,54] [–104,91; –73,25] [–96,17; –71,83] [–98,47; –66,69] [–109,81; –54,99] [–83,95; –52,85] [–75,99; –55,45] [–66,59; –61,89] [–89,49; –36,31] [–74,18; –45,46] [–61,64; –56,90] [–67,81; –43,55] [–72,63; –38,57] [–65,20; –44,80] [–76,30; –25,30] [–46,00; –41,34] [–71,07; –9,93] [–32,05; –30,21] [–30,87; –29,09] [–76,74; –57,35] –110,00 –99,00 –97,84 –94,80 –89,08 –84,00 –82,58 –82,40 –68,40 –65,72 –64,24 –62,90 –59,82 –59,27 –55,68 –55,60 –55,00 –50,80 –43,67 –40,50 –31,13 –29,98 –67,04 –100 100 –50 50 0 Avis 2010, Rosuvastatina 20 mg Avis 2010, Rosuvastatina 10 mg McCrindle 2003,Atorvastatin 10 mg–20 mg Braamskamp 2015, Pitavastatina 4 mg Braamskamp 2015, Pitavastatina 2 mg Braamskamp 2015, Pitavastatina 1 mg de Jongh 2002, Simvastatina 40 mg de Jongh 2002, Simvastatina 20 mg de Jongh 2002, Simvastatina 10 mg Knipscheer 1996, Pravastatina 20 mg Knipscheer 1996, Pravastatina 10 mg Knipscheer 1996, Pravastatina 5 mg Rodenburg 2006, Pravastatina 40 mg Weigman 2004, Pravastatina 20 mg–40 mg Clauss 2005, Lovastatina 40 mg Clauss 2005, Lovastatina 20 mg Van der Graaf 2008, Simvastatina 40 mg/Ezetimibe 10 mg Van der Graaf 2008, Simvastatina 10 mg–20 mg–40 mg/Ezetimibe 10 mg Stein 1999, Lovastatina 20 mg Stein 1999, Lovastatina 40 mg Stein 1999, Lovastatina 10 mg Avis 2010, Rosuvastatina 5 mg Heterogeneity: I 2 = 99,5%, tau 2 = 416,6, p < 0,0001 Modelo de efeitos aleatórios Estudo Total Total DP DP Diferença média Estatinas Placebo Média Média MD W (aleatório) IC95% Apêndice 4 – Gráfico mostrando o efeito da terapia com estatinas nos níveis de colesterol lipoproteína de alta densidade (HDL). 26 27 106 106 106 106 26 63 63 18 18 1428 1053 35 44 35 44 140 63 126 126 18 90 42 49,80 50,20 48,41 48,00 47,66 49,00 44,88 50,70 49,05 46,80 46,79 50,20 50,00 55,30 49,80 46,80 47,25 50,30 48,16 50,20 54,00 51,41 9,80 10,60 10,00 12,00 0,86 0,87 16,13 12,10 10,13 1,02 0,90 10,01 13,00 13,20 11,20 1,02 1,02 10,09 15,48 11,60 11,00 16,67 27 108 120 120 15 6 16 61 59 69 19 15 6 6 19 69 60 47 27 69 88 27 52,90 52,90 48,48 48,00 47,47 48,78 44,37 49,90 48,08 45,32 45,24 48,21 48,00 52,90 47,20 44,00 44,44 47,31 44,37 45,60 48,00 44,37 10,90 10,90 9,00 3,23 0,87 0,89 9,00 10,50 14,05 1,04 1,55 13,57 3,38 10,90 8,60 1,02 1,04 15,70 9,00 9,00 9,70 3,38 –3,10 –2,70 –0,07 0,00 0,19 0,22 0,51 0,80 0,97 1,48 1,55 1,99 2,00 2,40 2,60 2,80 2,81 2,99 3,79 4,60 6,00 7,04 1,52 [–8,68; 2,48] [–8,43; 3,03] [–2,62; 2,48] [–3,98; 3,98] [–0,03; 0,41] [–9,85; 10,87] [–2,53; 4,13] [–2,87; 4,81] [1,12; 1,84] [1,08; 2,02] [–1,74; 5,72] [–2,18; 6,18] [–4,13; 8,93] [–2,76; 7,96] [2,44; 3,16] [2,44; 3,18] [–1,18; 7,16] [–6,36; 13,94] [–1,21; 10,41] [2,33; 9,67] [–3,50; 17,58] [0,75; 2,30] [0,00; 0,44] 1,6% 1,6% 5,0% 2,8% 10,9% 10,9% 0,5% 3,6% 3,1% 2,6% 1,3% 1,8% 10,7% 10,7% 2,6% 0,6% 0,5% 100% 1,5% 3,2% 3,0% 10,7% 10,6% –15 –10 –5 15 10 5 0 Avis 2010, Rosuvastatina 10 mg Avis 2010, Rosuvastatina 20 mg Avis 2010, Rosuvastatina 5 mg de Jongh 2002, Simvastatina 40 mg de Jongh 2002, Simvastatina 20 mg de Jongh 2002, Simvastatina 10 mg Stein 1999, Lovastatina 20 mg Stein 1999, Lovastatina 40 mg Stein 1999, Lovastatina 10 mg Knipscheer 1996, Pitavastatina 5 mg Clauss 2005, Lovastatina 20 mg Clauss 2005, Lovastatina 40 mg Van der Graff 2008, Simvastatina 40 mg/Ezetimibe 10 mg Van der Graff 2008, Simvastatina 10 mg–20 mg–40 mg/Ezetimibe 10 mg Rodenburg 2006, Pitavastatinaa 40 mg Knipscheer 1996, Pitavastatinaa 10 mg Knipscheer 1996, Pitavastatinaa 20 mg Braamskamp 2015, Pitavastatina 4 mg Braamskamp 2015, Pitavastatina 2 mg Braamskamp 2015, Pitavastatina 1 mg Weigman 2004, Pitavastatina 20 mg–40 mg McCrindle 2003,Atorvastatina 10 mg–20 mg Heterogeneity: I 2 = 93,5%, tau 2 = 1,426, p < 0,0001 Modelo de efeitos aleatórios Estudo Total Total DP DP Diferença média Estatinas Placebo Média Média MD W (aleatório) IC95% 820